Actimed Therapeutics secures additional £4.75m funding in Series A extension round, almost doubling Series A proceeds
Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, today announces it has raised a further £4.75m in an extension to its recent Series A financing round which was ...
Source: pharmiweb.com